Trials / Unknown
UnknownNCT03600974
A New System for GERD Diagnosis and Treatment
A New System for Diagnosis and Treatment of Gastroesophageal Refulx Diseases : Based on Endoscopy, pH Parameter, Impedence Parameter, High Resolution Manometry and Psychology
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 200 (estimated)
- Sponsor
- Capital Medical University · Academic / Other
- Sex
- All
- Age
- 18 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
This is a pilot study measuring a new diagnosis and treatment system "EAISMLP" in adult patients with gastroesophageal reflux disease (GERD).
Detailed description
The investigators created a new diagnosis and treatment system for gastroesophageal reflux disease (GERD). The system based on endoscopy, 24h esophageal pH-impedance monitoring, esophagus high resolution manometry and psycological condition.the investigators named it as "EAISMLP" symptom. Each letter in "EAISMLP" is responsible for a typical character and treatment. Subjects will be subtyped according to "EAISMLP" system and underwent treatment, and will be follow up for 6 months and 1 years.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Stretta | Stretta for Endoscopy-E(+),Acid-A(+),Reflux-symptom association-S(+) or lower oesophageal sphincter-L(+) group |
| PROCEDURE | Laparoscopic Nissen fundoplication | Laparoscopic Nissen fundoplication for E(+),A(+) or L(+) group |
| DRUG | Probiotic Agent | Probiotic Agent for I(+)G/W;Live Bacillus Licheniformis Cranules 0.5g bid; Bifidbacterium 0.63g bid |
| DRUG | PPI | PPIs for A(+),E(+)or S(+) patients: Nexium 20mg Qd/Bid;Lansoprazole 30mg Qd/Bid;omeprazole 10mg-30mg Qd-Bid;Rabeprazole 10mg Qd/Bid;Esomeprazole 20mg Qd/Bid;Pantoprazole 40mg Qd/Bid |
| DRUG | Prokinetic Motility Agents | Prokinetic Motility Agents for M(+) group; Mosapride 5mg Tid; Domperidone 10mg Tid |
| DRUG | Neuromodulators | Neuromodulators for P(+) or S(+);Flupentixol and Melitracen 1# bid; |
Timeline
- Start date
- 2019-02-01
- Primary completion
- 2020-07-01
- Completion
- 2021-07-01
- First posted
- 2018-07-26
- Last updated
- 2019-02-05
Source: ClinicalTrials.gov record NCT03600974. Inclusion in this directory is not an endorsement.